Risperidone in the treatment of negative symptoms of schizophrenia

Carman, John S.; Peuskens, Joseph; Vangeneugden, A

doi:10.1097/00004850-199511000-00001

Cited by 119 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is consistent with most previous studies, which found that psychiatric symptomatology improves more with risperidone than with typical NLP treatments (Peuskens, 1995;Rabinowitz & Davidson, 2001;Yen et al, 2004). Risperidone possesses serotonergic and dopaminergic antagonist properties that may make it more effective than typical NLPs in the treatment of SC symptoms (Carman et al, 1995).…”

Section: Discussionsupporting

confidence: 92%

Long-term effects of risperidoneversushaloperidol on verbal memory, attention, and symptomatology in schizophrenia

Rémillard

Pourcher

Cohen

2007

J Int Neuropsychol Soc

View full text Add to dashboard Cite

There is evidence in the literature that cognitive functions in schizophrenia (SC) may be improved by atypical neuroleptics (NLPs) in contrast to typical medication, but there is still controversy regarding this apparent superiority of atypical drugs. In this study, we assessed the differential effects of risperidone and haloperidol on verbal memory, attention, and psychiatric symptoms in SC. The performance of 28 SC participants, randomly assigned to risperidone (2-6 mg0day) or haloperidol (2-40 mg0day), was compared with that of healthy controls. The California Verbal Learning Test (CVLT), the d2 Cancellation Test, and the Positive and Negative Symptoms Scale were administered at baseline and 3, 6, and 12 months. Relative to controls, all SC participants showed markedly impaired verbal memory and processing speed at each assessment period. There was no differential effect between the two NLPs on CVLT and d2 performance. However, risperidone was more effective than haloperidol in reducing psychiatric symptoms. Improvement in symptom severity was not associated with improvement in neurocognitive performance on these specific tests. Neither conventional nor atypical neuroleptic medications improved neurocognitive functioning over a 12-month follow-up, suggesting that psychopathological improvement under risperidone is independent of cognitive function. (JINS, 2008, 14, 110-118.)

show abstract

Section: Discussionsupporting

confidence: 92%

Long-term effects of risperidoneversushaloperidol on verbal memory, attention, and symptomatology in schizophrenia

Rémillard

Pourcher

Cohen

2007

J Int Neuropsychol Soc

View full text Add to dashboard Cite

show abstract

“…It also possesses some short-acting norepinephrine receptor antagonist activity, as well as some antihistaminergic activity (Leysen et al 1988;Janssen et al 1988). Studies have shown that it is at least as effective as the typical neuroleptics in patients with acute and chronic schizophrenia with positive and/or negative symptoms (Chouinard et al 1993;Hoyberg et al 1993;Marder and Meibach 1994;Carman et al 1995;Huttunen et al 1995;Peuskens and the Risperidone Study Group 1995) and that it is better tolerated than typical neuroleptics in terms of extrapyramidal side effects (Geddes et al 2000).…”

mentioning

confidence: 99%

Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study

Sechter

Fleurot

Rein

et al. 2002

Neuropsychopharmacology

106

View full text Add to dashboard Cite

Schizophrenia is a chronic and disabling disorder with a lifetime prevalence of approximately 1% (American Psychiatric Association 1994). It results in significant long-term functional handicap, severely impairs the quality of life of both the patient and the caregivers and places a considerable financial burden on society.The clinical efficacy of amisulpride against acute psychotic symptoms at high doses (400-800 mg/day) and prominent negative symptoms at low doses (50-300 mg/day) may be explained by its preferential affinity for pre-synaptic dopaminergic D 2 and D 3 autoreceptor subtypes at low doses, while higher doses result in predominant antagonism of post-synaptic dopamine receptors (Perrault et al. 1997;Schoemaker et al. 1997). It also shows selectivity for dopamine receptors in limbic and hippocampal structures, rather than striatal structures, thus suggesting a lower propensity to induce extrapyramidal effects than seen with the classical antipsychotics (Perrault et al. 1997). Studies in

show abstract

“…Doses of risperidone varied and were fixed or flexible, ranging from a fixed minimum of 1 mg, given to one group in the multicentre European trial (Peuskens 1995 263 ), to a fixed maximum of 16 mg (Peuskens 1995, Chouinard 1993 Risperidone was compared with amisulpride in two studies, with clozapine in six, with olanzapine in seven, with quetiapine in one, and with ziprasidone in two.…”

Section: Interventionsmentioning

confidence: 99%

“…In two reviews 205,274 it was found that risperidone was more effective in relieving the negative symptoms of schizophrenia than typical antipsychotic drugs. The Cochrane review did not find this.…”

Section: Systematic Reviews Identified In the Original Reviewmentioning

confidence: 99%

A systematic review of atypical antipsychotic drugs in schizophrenia

Bagnall

Jones

Ginnelly

et al. 2003

Health Technol Assess

151

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAA systematic review of atypical antipsychotic drugs in schizophrenia NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/20/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.Reviews in Health Technology Assessment are termed 'syst...

show abstract

Risperidone in the treatment of negative symptoms of schizophrenia

Cited by 119 publications

References 0 publications

Long-term effects of risperidoneversushaloperidol on verbal memory, attention, and symptomatology in schizophrenia

Long-term effects of risperidoneversushaloperidol on verbal memory, attention, and symptomatology in schizophrenia

Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study

A systematic review of atypical antipsychotic drugs in schizophrenia

Contact Info

Product

Resources

About